Kevin A. Schulman

Visiting Scholar

Journal Articles

  1. Market-Based Solutions to Antitrust Threats—The Rejection of the Partners Settlement

    Regina E. Herzlinger, Barak D. Richman and Kevin A. Schulman

    Keywords: health care; health care industry; health care policy; health care services; antitrust; Health Care and Treatment; Health Industry; United States;

    Citation:

    Herzlinger, Regina E., Barak D. Richman, and Kevin A. Schulman. "Market-Based Solutions to Antitrust Threats—The Rejection of the Partners Settlement."New England Journal of Medicine 372, no. 14 (April 2, 2015): 1287–1289. View Details
  2. Innovation in Health Care Education: A Call to Action

    Regina E. Herzlinger, Vasant Kumar, Kevin Schulman and Karen Staman

    Health care administration educators are at a crossroads: the health care sector is rife with inefficiencies, erratic quality, unequal access, and sky-high costs, complex problems which call for innovative solutions, and yet, according to our content analysis of top U.S. health administration schools and a recent article in the Lancet, our educational systems focus their curricula on isolated,theoretical subjects, such as analytics and quantitative problem solving, rather than the team-oriented, practical problem-solving skills required for innovation. All too often, when graduates of these programs enter the workforce, they find themselves unequipped to meet the challenges for innovation of 21st century health care.

    Keywords: health care; health care education; Education; Health; Health Care and Treatment; Health Industry; Education Industry;

Cases and Teaching Materials

  1. Alnylam: Building a Biotechnology Powerhouse

    Kevin Schulman

    Alnylam is an early stage biomedical technology focused on commercial development of a novel technology platform, siRNA. This technology offered promise to treat rare genetic disorders that could not be treated with other technologies. Alnlyam's development entailed the aggressive assembly of an intellectual property portfolio around their core platform technology, the development of a licensure strategy with large-cap pharmaceutical firms (which included the co-development of a delivery platform for their technology), and finally a clinical development strategy. The case illustrates the challenges of drug development based on novel scientific frameworks, as well as the promise of "personalized" medicine.

    Keywords: Technological Innovation; Commercialization; Health Disorders; Intellectual Property; Biotechnology Industry;

    Citation:

    Schulman, Kevin. "Alnylam: Building a Biotechnology Powerhouse." Harvard Business School Case 316-113, June 2016. View Details
  2. Product Portfolio Management at Genentech

    Kevin Schulman and Jamie Gresh

    Genentech, long the darling of the biotechnology industry, was acquired by Swiss pharmaceutical company Roche in 2009. The combined company retains the name Genentech in the US, but must now move to achieve the promises made at the time of this merger—to build from what made Genentech great. One of the key tasks for Genentech CEO Ian Clark and CFO Ashraf Hanna was to implement a new portfolio management process for the combined entity. This case explores the goals of the portfolio management process, and allows students to actively participate in the portfolio management exercise. The case includes cost and income projections for 12 products that need to be reviewed and approved.

    Keywords: pharmaceutical industry; portfolio management; United States; drug development; Postmerger integration; Marketing Strategy; Mergers and Acquisitions; Biotechnology Industry; Pharmaceutical Industry; United States;

    Citation:

    Schulman, Kevin, and Jamie Gresh. "Product Portfolio Management at Genentech." Harvard Business School Case 317-012, July 2016. View Details
  3. Aggressive Growth Plans For Zimmer Spine

    Kevin Schulman and Miranda Shaw

    Steve Healy, the President of Zimmer Spine, has to transform his organization into a market leader. Zimmer is a major medical device firm, but the Spine division has underperformed and its core technology did not get the expanded FDA label that had been expected. The case reviews the industry, the competitive landscape, and the potential growth strategies for Zimmer Spine to consider.

    Keywords: medical device; organizational innovation; organizational growth; Organizations; Growth and Development Strategy; Medical Devices and Supplies Industry;

    Citation:

    Schulman, Kevin, and Miranda Shaw. "Aggressive Growth Plans For Zimmer Spine." Harvard Business School Case 316-106, June 2016. View Details
  4. Health Systems in the Developing World

    Kevin Schulman, Muhammed Pate and Gary Carbell

    This teaching note offers an approach to the evaluation of health care markets globally. The note prepares students with a set of questions about the organization of core elements of the health care system. The organization of these elements can vary across markets, and can vary in terms of the different roles of the public and private sector in financing and delivery of health care services.

    Overall, the framework provides an opportunity for a structured analysis of any market in health care, and provides students with a comprehensive approach to assessing the current health care market. Students can build from this framework with their own assessments of potential opportunities for business or policy innovation within the market.

    Citation:

    Schulman, Kevin, Muhammed Pate, and Gary Carbell. "Health Systems in the Developing World." Harvard Business School Background Note 316-112, May 2016. View Details
  5. BDP Pharmaceuticals

    Kevin Schulman, Emma Rasiel and Suresh Balu

    Susan Durham has just been hired as the Chief Financial Officer of Blue Devil Pharmaceuticals (BDP). Her charge is to understand the optimal pathway for the development of a novel molecule, BDP-1, to understand the cost of drug development, the market opportunity, and the optimal financing strategy for the development of this technology. The case includes a unique simulation model that examines key unknowns in making this assessment including the volatility in the financial markets, volatility in in-licensing markets. Financial strategies include: go-alone, partner with a pharmaceutical company, receive financing from from a private equity firm, or there is an option to sell the molecule. Students can see how uncertainty in the development and financing strategy can impact the value of the firm to shareholders.

    Keywords: finance; entrepreneurship; Finance; Entrepreneurship;

    Citation:

    Schulman, Kevin, Emma Rasiel, and Suresh Balu. "BDP Pharmaceuticals." Harvard Business School Simulation 317-702, August 2016. View Details
  6. Blue D Pharmaceuticals

    Kevin Schulman, Emma Rasiel and Suresh Balu

    Susan Durham has just been hired as the Chief Financial Officer of Blue Devil Pharmaceuticals (BDP). Her charge is to understand the optimal pathway for the development of a novel molecule, BDP-1, to understand the cost of drug development, the market opportunity, and the optimal financing strategy for the development of this technology. The case includes a unique simulation model that examines key unknowns in making this assessment including the volatility in the financial markets, volatility in in-licensing markets. Financial strategies include: go-alone, partner with a pharmaceutical company, receive financing from a private equity firm, or there is an option to sell the molecule. Students can see how uncertainty in the development and financing strategy can impact the value of the firm to shareholders.

    Keywords: finance; entrepreneurship; Finance; Entrepreneurship;

    Citation:

    Schulman, Kevin, Emma Rasiel, and Suresh Balu. "Blue D Pharmaceuticals." Harvard Business School Case 317-014, July 2016. View Details
  7. Improving Melanoma Screening: MELA Sciences

    Regina E. Herzlinger, Kevin Schulman and Frédéric Dijols

    MELA is a start-up medical device company looking to develop a novel technology to help physicians diagnose a deadly skin cancer, melanoma. The case reviews the FDA medical device development process, the development path pursued by MELA, and the regulatory and business trajectory of the firm. In the end, MELA raised $100 million for the development of this technology, and had $1 million in revenue after launch. The case offers opportunities to have discussions focused on device development, market assessment, regulatory strategy, and launch strategy.

    Keywords: healthcare industry; health care; Health; Health Care and Treatment; Health Testing and Trials; Health Industry; United States;

    Citation:

    Herzlinger, Regina E., Kevin Schulman, and Frédéric Dijols. "Improving Melanoma Screening: MELA Sciences." Harvard Business School Case 315-042, December 2014. (Revised August 2015.) View Details
  8. MedCath Corporation (C)

    Regina E. Herzlinger, Kevin Schulman and F. Fallon Upke

    MedCath is a horizontally integrated chain of heart hospitals that partners with local cardiologists. It claims that its focus leads to better and cheaper results than those of an everything-for-everybody general hospital. Community hospitals generally vehemently oppose their entry into a new area. What options does MedCath have?

    Keywords: Medical Specialties; Market Entry and Exit; Service Delivery; Conflict and Resolution; Horizontal Integration; Health Industry;

    Citation:

    Herzlinger, Regina E., Kevin Schulman, and F. Fallon Upke. "MedCath Corporation (C)." Harvard Business School Supplement 315-018, February 2015. View Details
  9. Savannah Informatics

    Kevin Schulman

    John Muthee and Justus Paul are recent graduates of medical school and a unique program in clinical informatics. They return to Nairobi, Kenya with a passion to make a difference in their community. They have a team they know well, but need to find a project concept for a new company. Eventually, they focus on what they believe to be a significant opportunity—supporting health insurance with an electronic eligibility verification and claim submission. They develop a business concept, but have challenges breaking into the market and attracting investment. They finally land a grant (non-dilutive financing) from the US Agency for International Development (USAID) and build their product. Having proven that the technology works, can they scale their solution?

    Keywords: entrepreneurship; Kenya; information systems; Entrepreneurship; Kenya; Africa;

    Citation:

    Schulman, Kevin. "Savannah Informatics." Harvard Business School Case 316-111, January 2016. View Details
  10. Health Catalyst Case Study

    Kevin Schulman and Suresh Balu

    Dan Burton, Health Catalyst CEO (HBS Baker Scholar), and Tom Burton, Health Catalyst Senior Vice President of Product Development and co-founder closed on a $41 million investment round. Their firm was one of the hottest companies in the health information technology field. They provided core data warehouse technology to enable analytics from electronic health record systems. Still, they faced significant competition in this space. Could they execute against their vision?

    Keywords: entrepreneurship; information technology; service management; strategy; operations management;

    Citation:

    Schulman, Kevin, and Suresh Balu. "Health Catalyst Case Study." Harvard Business School Case 316-098, February 2016. View Details
  11. AbbVie

    Kevin Schulman, Laura Little, Samyukta Mullangi and Stephen Schleicher

    This case focuses on the impact of a novel regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars market entrants, and a series of adverse financial forecasts for AbbVie. Given all of these risks, did the acquisition add value to shareholders?

    AbbVie made headlines in March 2015 when it announced its $21 billion acquisition of Pharmacyclics. AbbVie, a research-based pharmaceutical company, was founded in 2013 when Abbott split into AbbVie and Abbott Laboratories. Pharmacyclics is a biotechnology company that had received FDA approval in late 2013 for its flagship asset Imbrivica (ibrutinib), a biologic treatment for chronic lymphocytic leukemia and two other even rarer blood malignancies. Entering its second year on the market, Imbrivica was considered a breakthrough, with revenue expectations of $1 billion in 2015. At the time of the acquisition, AbbVie received more than 60% of its sales from the biologic drug Humira, a biologic agent used to treat several autoimmune diseases and malignancies. However, Humira would soon lose patent protection and face competition from the new class of follow-on biologics, or biosimilars.

    Keywords: Pharmaceutical Company; M&A Valuation; AbbVie; health care; Health Care and Treatment; Pharmaceutical Industry; Health Industry; United States;

    Citation:

    Schulman, Kevin, Laura Little, Samyukta Mullangi, and Stephen Schleicher. "AbbVie." Harvard Business School Case 316-095, May 2016. View Details